Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states

Author:

Müller Thomas R.1ORCID,Sekine Takuya1ORCID,Trubach Darya2ORCID,Niessl Julia1ORCID,Chen Puran1,Bergman Peter345ORCID,Blennow Ola367ORCID,Hansson Lotta89,Mielke Stephan1011ORCID,Nowak Piotr3712ORCID,Vesterbacka Jan37,Akber Mira1,Olofsson Anna13ORCID,Amaya Hernandez Susana Patricia2ORCID,Gao Yu1,Cai Curtis1ORCID,Söderdahl Gunnar614ORCID,Smith C. I. Edvard31011ORCID,Österborg Anders89,Loré Karin15ORCID,Sällberg Chen Margaret16ORCID,Ljungman Per1117ORCID,Ljunggren Hans-Gustaf1,Karlsson Annika C.1318ORCID,Saini Sunil Kumar2ORCID,Aleman Soo37ORCID,Buggert Marcus1ORCID

Affiliation:

1. Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.

2. Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, Denmark.

3. Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.

4. Department of Laboratory Medicine, Clinical Immunology, Karolinska Institutet, Stockholm, Sweden.

5. Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.

6. Department of Transplantation, Karolinska University Hospital, Stockholm, Sweden.

7. Department of Medicine Huddinge, Infectious Diseases, Karolinska Institutet, Stockholm, Sweden.

8. Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.

9. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

10. Department of Laboratory Medicine, Biomolecular and Cellular Medicine, Karolinska Institutet, Stockholm, Sweden.

11. Department of Cellular Therapy and Allogeneic Stem Cell Transplantation (CAST), Karolinska Comprehensive Cancer Center, Karolinska University Hospital Huddinge, Stockholm, Sweden.

12. Laboratory for Molecular Infection Medicine Sweden MIMS, Umeå University, Umeå, Sweden.

13. Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.

14. Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.

15. Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

16. Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden.

17. Department of Medicine Huddinge, Hematology, Karolinska Institutet, Stockholm, Sweden.

18. Karolinska University Laboratory, Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.

Abstract

Suboptimal immunity to SARS-CoV-2 mRNA vaccination has frequently been observed in individuals with various immunodeficiencies. Given the increased antibody evasion properties of emerging SARS-CoV-2 subvariants, it is necessary to assess whether other components of adaptive immunity generate resilient and protective responses against infection. We assessed T cell responses in 279 individuals, covering five different immunodeficiencies and healthy controls, before and after booster mRNA vaccination, as well as after Omicron infection in a subset of patients. We observed robust and persistent Omicron-reactive T cell responses that increased markedly upon booster vaccination and correlated directly with antibody titers across all patient groups. Poor vaccination responsiveness in immunocompromised or elderly individuals was effectively counteracted by the administration of additional vaccine doses. Functionally, Omicron-reactive T cell responses exhibited a pronounced cytotoxic profile and signs of longevity, characterized by CD45RA + effector memory subpopulations with stem cell–like properties and increased proliferative capacity. Regardless of underlying immunodeficiency, booster-vaccinated and Omicron-infected individuals appeared protected against severe disease and exhibited enhanced and diversified T cell responses against conserved and Omicron-specific epitopes. Our findings indicate that T cells retain the ability to generate highly functional responses against newly emerging variants, even after repeated antigen exposure and a robust immunological imprint from ancestral SARS-CoV-2 mRNA vaccination.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3